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Abstract
Background: The inferior colliculus, which receives almost all ascending and descending auditory
signals, plays a crucial role in the processing of auditory information. While the majority of the
recorded activities in the inferior colliculus are attributed to GABAergic and glutamatergic
signalling, other neurotransmitter systems are expressed in this brain area including opiate peptides
and their receptors which may play a modulatory role in neuronal communication.
Results: Using a perfusion protocol we demonstrate that morphine can inhibit KCl-induced
release of [3H]GABA from rat inferior colliculus slices. DAMGO ([D-Ala(2), N-Me-Phe(4), Gly(5)-
ol]-enkephalin) but not DADLE ([D-Ala2, D-Leu5]-enkephalin or U69593 has the same effect as
morphine indicating that µ rather than δ or κ opioid receptors mediate this action. [3H]GABA
release was diminished by 16%, and this was not altered by the protein kinase C inhibitor
bisindolylmaleimide I. Immunostaining of inferior colliculus cryosections shows extensive staining
for glutamic acid decarboxylase, more limited staining for µ opiate receptors and relatively few
neurons co-stained for both proteins.
Conclusion: The results suggest that µ-opioid receptor ligands can modify neurotransmitter
release in a sub population of GABAergic neurons of the inferior colliculus. This could have
important physiological implications in the processing of hearing information and/or other functions
attributed to the inferior colliculus such as audiogenic seizures and aversive behaviour.
Background
Sounds are first converted into neuronal signals in the
inner ear and then conveyed to the cerebral cortex via a
number of discrete brain areas including the inferior col-
liculus. Each of these areas receives ascending pathways
carrying signals from one or both ears and descending
pathways from higher brain centres. The current knowl-
edge of the neurochemical events occurring at each of
these brain centres is limited [1,2]. In the inferior collicu-
lus studies have been carried out to characterise the role of
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GABAergic neurons especially in sound localisation which
is believed to be one of the main functions of this brain
area [3,4]. Additionally the inferior colliculus has ben
implicated in audiogenic seizures and aversive behaviour
in which GABAergic neurons may also play an important
role. [5,6]
The neuronal communication occurring in the inferior
colliculus is likely to be influenced by modulatory systems
such as those of peptidergic neurotransmitters. Opiate
receptor gene expression, immunoreactivity and activity
in the inferior colliculus have been described [7-10]
although detailed studies on the effect of opiate on GABA
neurotransmitter release in this brain regions have not
been carried out.
Three classes of opiate peptides endorphins, dynorphins
and enkephalins activate µ, κ and δ-opiate receptors sub-
types respectively [12]. Recently a fourth related receptor
ORL1 activated by the peptide nociceptin has been identi-
fied and its distinct pharmacology has been described
[13]. All opiate receptors are associated with either Go or
Gi subunits and they mediate inhibitory actions including
pre-synaptic inhibition of neurotransmitter release. Dif-
ferent mechanisms of inhibition of neurotransmitter
release have been reported in various tissues and neurons
[14]. For example, in the periaqueductal gray stimulation
of opiate receptors and their associated G-proteins results
in the activation of potassium channels [15] while in the
hippocampus, inhibition of the GABAergic activity by
opioid is independent of potassium channel activation
[16].
In previous work we have established the presence and
distribution of opiate receptors in the adult and develop-
ing rat cochlea suggesting that the opiate system has a role
in hearing function [17,18]. In order to extend our knowl-
edge of the role of opiate system in hearing it is necessary
to characterise its presence and role also in the auditory
pathways. Our hypothesis was that opiate peptides can
modulate synaptic function in the auditory pathways by
pre-synaptically altering the release of other neurotrans-
mitters. To test this hypothesis we have used opiate drugs
to inhibit the release of [3H]GABA from inferior colliculus
slices
Results and Discussion
KCl-induced [3H]GABA release
Inferior colliculus slices pre-incubated with [3H]GABA
were perfused for 30 min and stimulated twice with 25
mM KCl to elicit neurotransmitter release. The eluate was
collected in 1 ml fractions and the released radioactivity
was assessed by scintillation counting. Figure 1 shows two
examples of typical release profiles from slices perfused
with either Krebs buffer throughout (control) or with
Krebs buffer for fractions 1–7 and with Krebs containing
1 µM morphine for the remaining fractions, where both
samples were stimulated with KCl at the time correspond-
ing to fraction 4 and 12. The two peaks were referred to as
S1 and S2 and occured approximately 2 fractions after the
application of KCl due to the buffer volume contained in
the tubes feeding into the incubation chamber. Values of
the radioactivity eluted are expressed as fractional release
which is the ratio of the radioactivity released in a partic-
ular fraction divided by the total amount of radioactivity
contained in the tissue immediately prior to that fraction.
The variation in the value of S1 of the two profiles shown
in Fig 1, both induced by KCl alone, reflects the variation
in amount of tissue present in each of the elution cham-
bers and illustrates the need for utilising the ratio of the
two peaks (S2/S1) of each elution profile as a mean to
detect the effect of the modulating drug.
Elution profile of KCl-stimulated [3H]GABA release from  inferior colliculus slices Figure 1
Elution profile of KCl-stimulated [3H]GABA release from 
inferior colliculus slices. Inferior colliculus slices were incu-
bated with 11 nM [3H]GABA for 30 min and perfused (0.5 
ml/min) with Krebs buffer for 30 min in a Brandel superfiltra-
tion apparatus. Fractions (1 ml) were then collected every 2 
min. Krebs buffer containing 25 mM KCl was loaded into the 
system at times corresponding to fraction 4 and 12 (short 
black lines) which elicited [3H]GABA release peaks in frac-
tions 6–7 and fraction 14–15. Krebs buffer containing modu-
lating drugs (1 µM morphine-long blue line) was added from 
the time corresponding to fraction 8. Scintillation fluid (3 ml) 
was added to the each fractionated eluate and to the solubi-
lized tissue samples and counted. Data are expressed as frac-
tional release which is calculated as the radioactivity released 
in one fraction divided by the amount of radioactivity present 
in the tissue just before that fraction. The two peaks from 
each elution profile are referred to as S1 and S2. The data 
from a representative experiment are shown.
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Morphine modulation of KCl induced [3H]GABArelease
The effect of different concentrations of morphine on KCl-
induced [3H]GABA release is shown in Figure 2. Both 1
µM and 5 µM but not 100 nM morphine caused a signifi-
cant decrease of [3H]GABA release from the inferior collic-
ulus slices. The effect of 1 µM morphine was antagonised
by the antagonist naloxone (10 µM) which was perfused
from one fraction before the addition of morphine. The
perfusion of naloxone alone did not cause a significant
effect on [3H]GABA release. These data strongly indicate
that morphine modulates the release of [3H]GABA via
activation of opiate receptors. The reduction in [3H]GABA
release calculated as the change in S2/S1 ratios in the pres-
ence and absence of morphine during S2 was 16% (p <
0.01). These data agree with previous reports on the pres-
ence of both GABA neurons and opiate receptors and pep-
tides in the inferior colliculus [7]. In addition a functional
inter-relationship is established between the two systems
which could be of physiological significance.
Specific role of µ opiate receptors
In order to establish which of the opiate receptor subtypes
are involved in the modulation of the [3H]GABA release,
morphine was substituted by either 1 µM DAMGO,
DADLE or U69593 which specifically activate µ, δ and κ
opiate receptors respectively (Fig. 3). Only DAMGO (1
µM) had a significant effect on [3H]GABA release, an effect
that was again antagonised by naloxone. DAMGO, as well
as morphine, reduced the amount of [3H]GABA release by
16% (p < 0.01) indicating that only µ opioid receptors
participate in the regulation of GABA release. Higher con-
centrations of DAMGO (5 µM) did not have greater effects
on [3H]GABA release (not shown). Data from our lab
(unpublished) and from others [9,10] indicate that
mRNA transcripts or receptor binding for all three opiate
receptor subtypes are present in the inferior colliculus.
Further work is required to establish the roles of the δ -
and κ-opioid receptors in the inferior colliculus.
Receptor desensitisation
A possible explanation for the relatively low effect of opi-
ate agonist on [3H]GABA release (16%) could be that
during the exposure to opiate agonists, down-regulation
of the opiate receptors may occur [19]. To address this
possibility experiments were carried out in the presence of
the protein kinase C inhibitor bisindolylmaleimide I
(BIM). BIM has been shown to inhibit receptor
Effect of morphine on KCl-stimulted [3H]GABA release Figure 2
Effect of morphine on KCl-stimulted [3H]GABA release. The 
ratio of the integration of the peaks S2 over S1 was calcu-
lated for each elution profile. Morphine (0.1, 1 and 5 µM) and 
naloxone (10 µM) alone or together were perfused as 
described in figure 1 but naloxone perfusion was started one 
fraction earlier. Data represent averages ± SEM. Labels on 
the x-axis indicate concentration of drugs present during S2. 
Statistical difference was calculated using one-way ANOVA. 
The data indicates that 1 and 5 µM morphine caused a statis-
tically significant 16% reduction of [3H]GABA release as 
compared to control (a) (p < 0.01). This effect of morphine 
was blocked by the antagonist naloxone (c) which had no 
effect on its own (b).
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Effect of subtype-specific opoid peptides on KCl-stimulted  [3H]GABA release Figure 3
Effect of subtype-specific opoid peptides on KCl-stimulted 
[3H]GABA release. DAMGO, DADLE and U69593 (1 µM) 
were perfused as described for morphine in Figure 1. Data 
represent averages ± SEM. Labels on the x-axis indicate con-
centration of drugs present during S2. Only the µ-opioid 
receptor specific neuropeptide DAMGO produced a statisti-
cally significant effect (p < 0.01, One way ANOVA) on KCl-
stimulted [3H]GABA release as compared to the controls (a) 
where no opiate drug was used. The effect of DAMGO was 
antagonised by 10 µM naloxone which was perfused from 
one fraction before the perfusion of DAMGO (b).
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desensitisation [20,21] and to reverse tolerance to opiate
drugs which involves opiate receptor desensitisation.
[22,23]. Because BIM is solubilised in DMSO additional
control assays were carried out to check for the effect of
the solvent. The results indicate (Fig. 4) that BIM had no
effect on the extent of morphine inhibition of [3H]GABA
release. While there is no direct proof that BIM had its
reported effect on the tissue, the data indicate that recep-
tor desensitisation may not be the cause of the relatively
low percentage effect of morphine.
Co-localisation of µ-opiate receptors and GABAergic 
neurons
Another possible explanation for the small (16%) reduc-
tion of [3H]GABA release by opiate agonists may be the
limited number of GABAergic neurons that express opiate
receptors. To address this question inferior colliculi slices
were double labelled with guinea pig antibodies against µ-
opioid receptors and with rabbit antibodies against
glutamic acid decarboxylase (the enzyme uniquely
responsible for the synthesis of GABA) Species specific
secondary antibodies conjugated to red and green fluoro-
chromes allowed the detection of both antigens on the
same slide (Fig. 5). Although these results were qualitative
it was evident that staining of glutamic acid decarboxylase
was more extensive than that of µ-opiate receptors and
that only a few GABAergic neurons showed co-localisa-
tion of µ-opiate receptors. These data are consistent with
the proposal that only a sub-population of GABAergic
neurons are under the influence of opiate receptors. Estab-
lishing the nature of the GABAergic neurons that express
opiate receptors will be an important task in understand-
ing the role of opiate signalling in the inferior colliculus.
Conclusions
This study has demonstrated that in the rat inferior collic-
ulus slices opiate agonists can inhibit KCl-induced
[3H]GABA release via activation of the µ-opiate receptor
subtype. The amount of [3H]GABA released in presence of
opiate agonists was 16% lower than in control slices. This
relatively low level of decrease is probably not due to
receptor desensitization occurring during the assay but
Effect of protein kinase C inhibitor bisindolylmaleimide I  (BIM) on morphine modulation of [3H]GABA release Figure 4
Effect of protein kinase C inhibitor bisindolylmaleimide I 
(BIM) on morphine modulation of [3H]GABA release. BIM is 
reported to reduce receptor desensitization and was used 
here to test whether morphine would elicit a bigger effect on 
[3H]GABA release in the presence of BIM. BIM is initially dis-
solved in DMSO whose effect on [3H]GABA release was also 
tested. BIM (1 µM) was present throughout the perfusion 
where indicated. Data represent averages ± SEM. Labels on 
the x-axis indicate concentration of morphine present during 
S2. The data show that morphine caused a reduction of 
[3H]GABA release as shown in Figure 2 but there was no sta-
tistical difference between experiments with or without BIM 
(One way ANOVA).
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Confocal microscopy of cryosection of inferior colliculus  slices stained with anti glutamic acid decarboxylase (green)  and anti µ-opioid receptor antibodies (red) Figure 5
Confocal microscopy of cryosection of inferior colliculus 
slices stained with anti glutamic acid decarboxylase (green) 
and anti µ-opioid receptor antibodies (red). A : Central 
nucleus of inferior colliculus. B: Pericentral nucleus of infe-
rior colliculus. Arrow head: example of GABAergic neurons 
not containing µ-opioid receptor (Green). Arrows: example 
of GABAergic neuron containing µ-opioid receptor (Yellow).
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rather to a relatively small population of GABAergic neu-
rons in the inferior colliculus expressing µ-opiate recep-
tors. The small effect of the opiate compounds could also
indicate that modulation of GABA release is not their
major role, but it could still be of physiological
significance.
Together with its reported role in audiogenic seizures and
aversive behaviour, the inferior colliculus is an important
neuronal centre for auditory processing containing both
ascending and descending fibres. The identification of the
role of opiate peptides and possibly other modulatory sys-
tem in the inferior colliculus and other areas of the audi-
tory pathway may allow a better understanding of the
mechanism of the hearing system and possibly offer a tar-
get for therapeutic intervention in hearing dysfunction.
Alternatively, elucidation of the role opiate peptides in the
inferior colliculus could provide information about regu-
lation of audiogenic seizures and aversive behaviour.
Methods
Materials
Opiate agonist and antagonists, (Morphine, DAMGO [d-
Ala(2), N-Me-Phe(4), Gly(5)-ol]-enkephalin, DADLE [D-
Ala2, D-Leu5]-enkephalin, U69593 and naloxone were
purchased from SIGMA, UK. Antibodies against µ-opiate
receptor AB1774 (guinea pig polyclonal) and glutamic
acid decarboxylase AB1511 (rabbit polyclonal) and spe-
cies specific pre-absorbed secondary antibodies (donkey
anti rabbit IgG FITC and donkey anti guinea pig IgG rhod-
amine) were purchased from Chemicon UK. Both
antibodies were raised against synthetic peptides, and
have been used in several immunocytochemical investiga-
tions of rat tissue. [24,25] AB1511 recognises the two iso-
forms of the enzyme in a Western blot (65/68 KDa) while
antibody AB1511 recognises µ-opiate receptors immuno-
cytochemically in the same tissues as other simlilar anti-
bodies and by insitu hybridisation (Chemicaon data
sheets, http://www.chemicon.com) Krebs carbonate
buffer: NaCl 118 mM, KCl 4.84 mM, CaCl2 2.4 mM,
NaHCO3 25 mM, MgSO4 1.8 mM KH2PO4 1.2 glucose 9.5
mM.
Animals
Sprague Dawley rats, approximately 200 g, were obtained
from UCL Biological Services. All animal experiments
were carried out in accordance to the Animal (Scientific
Procedure) Act 1986, UK.
Slices preparations
Rats were stunned and killed by cervical dislocation. The
skull was opened and the whole brain removed. The infe-
rior colliculus was dissected out by two coronal transec-
tions, the first between the cerebellum and the inferior
colliculus and the second between the inferior colliculus
and the superior coliculus. The slice was placed horizon-
tally and medullar tissue ventral to the inferior colliculus
was removed. The inferior colliculus was then placed on a
tissue chopper and sliced into 250 µm coronal sections.
Individual slices were separated under a dissecting micro-
scope in Krebs buffer.
Neurotransmitter release
As previously described, slices were incubated in 5 ml oxy-
genated (95% 02 / 5% CO2) Krebs buffer containing
GABA transaminase inhibitor aminooxyacetic acid (100
µM) at 32°C for 5 min [26]. [3H]GABA was added to give
a final concentration of 11 nM and incubated in a shaking
water bath for 30 min. Slices were distributed into 6
superfusion chambers between filter papers (Brandel
Superfusion System) and perfused at 0.5 ml/min with
oxygenated Krebs buffer. Following a 30 min perfusion
required to reach a steady state (non-stimulated)
[3H]GABA release, 2 min fractions (1 ml) were collected.
In order to evoke sub-maximal GABA release the slices
were perfused for 2 min with 25 mMKCl at 6–8 min and
22–24 min of the fractionation time (fraction 4 and 12).
At the end of each experiment (17 fractions) the tissue and
the filter papers were collected and incubated with 500 µl
Soluene-350 for 20 min and neutralised with 200 µl of
glacial acetic acid. Scintillant (Packard, Ultima Gold, 3
ml) was added to all tissue samples and eluted fractions
and the radioactivity was measured by scintillation count-
ing (Wallac 1409). Each drug treament was repeated in
several experiments as indicated in the figures and the
ratios of the S2/S1 peaks were averaged. Statistical signifi-
cance of the effect of treatments was analysed by one way
ANOVA using Excel (Microsoft, USA)
Immunocytochemistry
Inferior colliculi were dissected as decribed above and
fixed in 4% paraformaldehyde in phosphate buffer saline
(PBS: 137 mM NaCl, 2.7 mM KCl, 4.3 mM
Na2HPO4.7H2O, 1.4 mM KH2PO4 pH 7.3) for 1 hour,
washed 3 times in PBS and incubated overnight at 4°C in
30%sucrose in PBS. Coronal sections (20 µm) were cut
with a cryostat and collected on poly-lysine coated glass
slides and allowed to dry. The sections were blocked in
10% normal donkey serum diluted in PBS containing
0.25% bovine serum albumin and 0.1% Triton X-100
(PBS-A) for 30 min at room temperature. Subsequently,
they were incubated for 12 hours at 4°C with the combi-
nation of primary antibodies (rabbit anti GAD and guinea
pig anti mu opioid receptor) diluted 1:500 in PBS con-
taining 1% bovine serum albumin and 0.3% Triton X-100
(PBS-B).. Slides were washed 3 × 10 min with PBS-B and
incubated with secondary antibodies diluted 1:200 in
PBS-B, for 2 hours at room temperature. The secondary
antibodies used were donkey anti rabbit conjugated with
fluorescein (AP182F) and donkey anti guinea pig conju-Publish with BioMed Central    and   every 
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gated with rhodamine (AP182R). Finally, the sections
were rinsed in PBS-B for 10 min and in PBS for 2 × 10 min
and then mounted in Citifluor (Agar). The immunoreac-
tivity was visualized under the confocal microscopy (LSM
510 META Carl Zeiss, Germany).
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